STAT

Opinion: Strong action is needed to preserve the competitiveness of America’s life-science industries

We need to take steps to preserve U.S. leadership in the life sciences, given their importance to our economy.
Technicians work at Chinese biotech firm Sinovac in Beijing. The U.S. is a leader in the life sciences industry, but countries such as China are quickly gaining ground.

Living standards in the United States increasingly depend on the competitiveness of industries that compete internationally, particularly those that succeed by producing new innovations. The life-science sector, which includes pharmaceuticals, biotechnology, and medical devices, is one of those industries. It is also an American success story: Our country captures more than 40 percent of the world’s major patents in both pharmaceuticals and medical devices. But as I describe in a new written for the Information Technology and Innovation Foundation, the continued health of the U.S. life-sciences sector is at risk because a growing number of foreign competitors are making determined efforts to gain global market share, often using unfair tactics.

You’re reading a preview, subscribe to read more.

More from STAT

STAT2 min read
STAT+: Pharmalittle: We’re Reading About Plans For Generic Wegovy, Cough Syrup Warnings, And More
Biocon is developing a generic version of Novo Nordisk's Wegovy and is prepared to conduct a clinical trial next year if needed.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About Cigna Biosimilar Plans, A Vertex Deal In South Africa, And More
Cigna plans to make copies of AbbVie's Humira arthritis drug available with no out-of-pocket payment to eligible patients in the U.S.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About MorphoSys Drug Risks, An AstraZeneca Admission, And More
MorphoSys is dealing with a safety issue with pelabresib, the experimental treatment for myelofibrosis and centerpiece of its proposed $3 billion acquisition by Novartis.

Related Books & Audiobooks